key: cord-0256580-ay4vbp45
authors: Hawken, S. E.; Sellers, S. A.; Smedberg, J. R.; Ward, J. D.; Whinna, H. C.; Fischer, W. A.; Miller, M. B.
title: Longitudinal SARS-CoV-2 testing is punctuated by intermittent positivity and variable rates of cycle-threshold decline
date: 2021-10-01
journal: nan
DOI: 10.1101/2021.10.01.21264373
sha: b38f7959b7b3e46f50041861214c6d073bbe0feb
doc_id: 256580
cord_uid: ay4vbp45

The COVID-19 pandemic is complicated by cases of vaccine-breakthrough, re-infection, and widespread transmission of variants of concern (VOC). Consequently, the need to interpret longitudinal positive SARS-CoV-2 (SCV-2) tests is crucial in guiding clinical decisions regarding infection control precautions and treatment. Although quantitative tests are not routinely used diagnostically, standard diagnostic RT-PCR tests yield Ct values that are inversely correlated with RNA quantity. In this study, we performed a retrospective review of 72,217 SCV-2 PCR positive tests and identified 264 patients with longitudinal positivity prior to vaccination and VOC circulation. Patients with longitudinal positivity fell into two categories: short-term (207, 78%) or prolonged (57, 22%) positivity, defined as <= 28 (range 1-28, median 16) days and >28 (range 29- 152, median 41) days, respectively. In general, Ct values declined over time in both groups; however, 11 short-term positive patients had greater amounts of RNA detected at their terminal test compared to the first positive, and 5 patients had RNA detected at Ct < 35 at least 40 days after initial infection. Oscillating positive and negative results occurred in both groups, although oscillation was seen three times more frequently in prolonged-positive patients. Patients with prolonged positivity had diverse clinical characteristics but were often critically ill and were discharged to high-level care or deceased (22%). Overall, this study demonstrates that caution must be emphasized when interpreting Ct values as a proxy for infectivity, predictor of severity, or a guide for patient care decisions in the absence of additional clinical context.

The global burden of morbidity and mortality caused by SARS-CoV-2 (SCV-2) is 45 concentrated among vulnerable patients with comorbidities (1) . While most patients test negative 46 after 14 days, cases where patients remain RNA positive months later have been observed (2) (3) (4) (5) . During the study timeframe, four platforms were used by our laboratory for the detection 80 of SCV-2 RNA. Three of these assays, the Abbott Alinity m SARS-CoV-2 assay, Abbott 81

RealTime SARS-CoV-2 assay (Abbott Molecular Inc, Green Oaks, IL), and Cepheid Xpert® 82

Xpress SARS-CoV-2 (Cepheid, Sunnyvale, CA) had accessible cycle threshold data that was 83 exported from the instruments. Ct values were not available from an Emergency use 84 authorization (EUA) laboratory developed test that was used on a minority of specimens. To 85 adjust for cycle threshold reporting differences between instruments, 10 cycles were added to Ct 86 values from the Abbott M2000 assay to account for the 10 hidden cycles in the analysis software 87 (Abbott Molecular Inc, personal communication). 88 89 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Basic demographic information and SCV-2 test results (positive and negative tests, 91 specimen type, testing platform, Ct values) were abstracted from electronic medical records 92 (EMR) and the laboratory information system for all patients tested for SCV-2 RNA during the 93 study period. We queried these reports to identify patients with multiple positive tests and 94 examined the timing of positive tests to identify patients who had evidence of long-term 95 positivity of SCV-2 RNA. Patients who demonstrated positivity later than the 3 rd quartile of all 96 patients with multiple positive tests were considered "long-term" positive patients and were 97 investigated further by chart review. Manual chart review of the EMR was performed to abstract 98 patient age, gender, body mass index (BMI), hospital admission dates, and discharge disposition. 99

Medication exposure for long-term positive patients was collected via EMR reports. All descriptive statistics and data analysis were performed using R version 3.6.1 (11). 107 108

Between March 16 and October 15, 2020 our hospital performed 72,217 RT-PCR tests 111 for SCV-2 including 4,609 positive and 67,608 negative tests across six different specimen types 112 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 platforms: 18,057 EUA LDT, 7,014 Cepheid Xpert, 23,983 Abbott Alinity m, and 23,163 Abbott 114 RealTime (m2000). Among the 58,348 patients tested, 9,682 (16.6%) were tested multiple times 115 and 264 (0.45%) patients had at more than one positive test (Supplemental (terminal) positive test. Among these patients, terminal positive tests were median 9.8 cycles 133

higher compared to first positive tests, signaling lower amounts of RNA detected; however, 11 134 patients had higher amounts of RNA detected at their last positive test compared to first positive 135 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 1, 2021. Here we describe the natural history of SCV-2 RNA testing among all patients who tested 157 positive multiple times at our institution during a seven-month period, revealing complex 158 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. which will need to be investigated in future studies in order to better understand this 177 phenomenon and how it pertains to infectivity and the clinical course of these patients. 178

As the pandemic progresses in time, and VOC capable of high-titer and vaccine 179 breakthrough infections such as Delta gain in prevalence, longitudinal testing information with 180 variability in Ct values will become available for a greater number of patients. With the added 181 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Days between first and last positive test . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 1, 2021 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.10.01.21264373 doi: medRxiv preprint Figure S1 . Timeline of SCV-2 testing throughout study for patients with at least 2 positive SCV-274 Days since first positive test: prolonged positive patients with intermittent positive tests . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Risk factors for severity and 195 mortality in adult COVID-19 inpatients in Wuhan

Prolonged SARS-CoV-2 replication in an 206 immunocompromised patient

Prolonged Viral RNA Shedding in Patients with Coronavirus Disease

COVID-19-Lessons Learned and Questions Remaining